Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer

Inclusion Criteria: 1. Male patients aged from 18 to 75 years old; 2. The patients' ECOG score ≤ 2; 3. Prostate cancer patients in castration resistance stage (with or without distant metastasis): 1. Previous new endocrine therapy is ineffective; 2. Past treatment with too much citabine or cabatase is ineffective. 4. Have measurable or evaluable lesions; 5. The patients' main tissues and organs function well: 1. Liver function: ALT/AST \< 3 times the upper limit of normal value (ULN); 2. renal function: creatinine \< 220 μ mol/L; 3. Lung function: indoor oxygen saturation ≥ 95%; 4. Cardiac function: Left ventricular ejection fraction (LVEF)≥40% 6. Patients or their legal guardians voluntarily participate and sign the informed consent form. Exclusion Criteria: 1. Infectious diseases (such as HIV, active hepatitis B or C infection, active tuberculosis, etc.); 2. Feasibility evaluation screening proves that the transfection of targeted lymphocytes is less than 10% or the amplification under the co-stimulation of CD3/CD28 is insufficient (\< 5 times); 3. The vital signs are abnormal and those who cannot cooperate with the inspectors; 4. Those with mental illness or mental illness who can't cooperate with treatment and curative effect evaluation; 5. Highly allergic constitution or severe allergic history, especially those who are allergic to IL-2; 6. Subjects with systemic infection or local severe infection who need anti-infection treatment; 7. Complicated dysfunction of heart, lung, brain, liver, kidney and other important organs; 8. Patients with other tumors; 9. Doctors think that there are other reasons that can't be included in the treatment.